Vyznova (Neltependocel) Cornea Cell Therapy: Comprehensive Guide to Receiving Treatment Exclusively Available in Japan
- 2 days ago
- 5 min read
If your vision has been slowly clouding and you have been told that a corneal transplant may be your only option, you are not alone, and you may have more choices than you realize.
Access Vyznova (neltependocel) exclusively at Japan's leading specialized corneal centers. As your trusted gateway, we provide precise information to help you select a medical institution and corneal specialist well-suited to your unique needs, calmly and without pressure. From arranging direct online consultations with your potential surgeon to issuing official hospital referrals, we ensure your journey begins with clarity, reassurance, and expert guidance.
Introduction: Information for International Patients and Medical Professionals Regarding Corneal Endothelial Cell Therapy in Japan
Dealing with corneal endothelial dysfunction presents unique daily challenges: the persistent haze, the glare that makes mornings difficult, and the uncertainty about the future.
For decades, the standard treatment has been tissue transplantation, such as DSAEK or DMEK. These procedures are well established and have helped many people, yet they carry real burdens: the invasiveness of surgery, donor tissue shortages, and the long-term risk of graft rejection.
There is now another path. Vyznova (neltependocel) is a cultured corneal endothelial cell therapy developed and regulatory-approved in Japan. Rather than transplanting donor tissue, it delivers a localized injection of healthy, cultured corneal endothelial cells into the anterior chamber, offering an alternative to conventional corneal transplantation.
This guide is curated by an inter-institutional council of practicing Japanese ophthalmologists and corneal specialists, and serves as your direct gateway to five in-depth reports: [Clinical Outcomes in Japan], [Patient Eligibility Criteria], [Financial Structure & Costs], [the Surgical Guide for the Day of the Procedure], and [the International Patient Guide for Traveling to Japan].
Section 1: What Vyznova Is — Clinical Profile, Approval Status, and Real-World Results in Japan
Many patients tell us the hardest part is not knowing whether a treatment actually works. Here is what the evidence shows.
Vyznova (neltependocel) is the world's first regulatory-approved allogeneic cell therapy for corneal endothelial disease, licensed by Japan's PMDA in March 2023. Unlike traditional DSAEK/DMEK transplants, Vyznova uses a single, low-invasive micro-injection of cultured human corneal endothelial cells (cHCECs) directly into the anterior chamber.
Key Efficacy and Clinical Milestones in Japan
Addressing donor shortages: Advanced culturing technology allows cells from a single donor cornea to treat more than 100 recipient eyes, helping overcome the tissue scarcity that keeps so many patients waiting.
Proven results: In Japanese clinical trials, 91% of patients achieved a stable corneal endothelial cell density (ECD) of 1,000 cells/mm2 at 24 months, with safety sustained over 5 years.
Real-world restoration: 2024–2025 multi-center commercial data in Japan demonstrated rapid recovery within 6 months: corneal clarity was restored, central corneal thickness (CCT) decreased from a mean of 729 μm to 586 μm, and mean ECD reached 2,483 cells/mm2.
Outpatient recovery: The procedure requires minimal incisional sutures and is completed under local anesthesia, requiring 3 hours of face-down positioning post-injection.
Read the Full Report: [Clinical Outcomes in Japan]
Section 2: Are You a Candidate? Eligibility and Remote Assessment
One of the most stressful parts of seeking treatment abroad is the fear of traveling a long way only to be told you are not a candidate. We want to spare you that.
Determining eligibility involves a careful, multi-factor clinical review, and our specialist council recommends a thorough remote pre-screening consultation before you commit to any travel or expense.
Key Clinical Benchmarks and Criteria
Primary indications: advanced corneal endothelial dysfunction, including pseudophakic/aphakic bullous keratopathy (BK) and advanced Fuchs' endothelial corneal dystrophy (FECD).
Objective thresholds considered: Best-Corrected Visual Acuity (BCVA) below 0.5, a corneal endothelial cell density (ECD) below 500 cells/mm² (or unmeasurable), and central corneal thickness (CCT) at or above 630 μm due to active edema.
Factors that may exclude: irreversible stromal scarring, advanced glaucoma with uncontrolled IOP, or severe macular/retinal disease.
A practical requirement: the physical capacity to hold a strict face-down position for roughly 3 hours after the injection.
What You'll Need to Provide for a Remote Specialist Evaluation
To facilitate an objective eligibility determination, international applicants submit recent diagnostic records categorized into three distinct assessments:
Clinical history & basic metrics: disease progression, ocular surgical history, current BCVA, baseline IOP.
Anterior segment diagnostics: slit-lamp photography (with/without fluorescein), specular microscopy, anterior segment OCT.
Posterior segment evaluation: wide-field fundus photography, macular OCT, and Ganglion Cell Complex (GCC) analysis.
Read the Full Report: [Patient Eligibility Criteria]
Section 3: Understanding the Cost of Vyznova Treatment
We know that cost is often the question patients are most anxious to ask and most hesitant to voice. You deserve a straight answer.
For international patients, outside Japan's National Health Insurance system, the total cost is estimated at up to 20,000,000 JPY (approximately $135,000–$145,000 USD, depending on the exchange rate).
What Makes Up the Cost — and the Value Behind It
The therapy itself: The Japan's Ministry of Health, Labour and Welfare (MHLW) official reimbursement price for a single-use vial of Vyznova is 9,464,500 JPY, reflecting complex GMP biomanufacturing and lot-specific quality control.
Institutional fees & diagnostics: surgical fees for the intracameral injection, operating room use, baseline screenings, and the required 3-hour observation period.
What you receive: a low-invasive, single-procedure option that restores corneal clarity without a donor-tissue waiting list or the structural risks of a traditional graft.
Read the Full Report: [Financial Structure & Costs]
Section 4: What Happens on the Day — Surgical Procedure Guide
Fear of the unknown is often worse than the procedure itself, so here is exactly what your day will look like.
The Vyznova cell injection is a structured, micro-invasive outpatient procedure. Your total time at the institution is usually five to six hours, from admission to discharge, requiring only local anesthesia.
Step by Step
Before the procedure: clinical checks, anesthetic eye drops, and pupillary constriction.
The injection: a small 0.8–1.0 mm limbal paracentesis, scraping of host endothelial cells, cell suspension injection, and a precautionary suture.
Face-down positioning: a strict 3-hour face-down posture, letting gravity settle the cells onto Descemet's membrane.
Recovery & follow-up: no eye-rubbing or strenuous activity for 24 hours, then a topical antibiotic/steroid regimen and check-ups at Day 1, Week 1, and beyond.
Read the Full Report: [the Surgical Guide for the Day of the Procedure]
Section 5: Traveling to Japan for Vyznova — Your Medical Travel Guide
Planning medical travel while managing an eye condition can feel like a lot to carry alone. You will not have to.
Because this cellular therapy is currently available only in Japan, international patients follow a specific regulatory and scheduling framework, and we walk with you through every step.
Choosing a Hospital, Building Your Itinerary, and Getting Support
Selecting a partner hospital: access is currently limited to specialized corneal centers.
A model itinerary: a 21-day (3-week) stay — pre-operative imaging (Days 1–4), injection and acute tracking (Days 5–7), follow-up before travel clearance (Days 8–21).
Your medical travel coordinator: help with record translation, remote consultation scheduling, local logistics, and English medical summaries for follow-up care back home.
Read the Full Report: [the International Patient Guide for Traveling to Japan]
Clinical Inquiry and Case Evaluation
If someone you love has been diagnosed with corneal endothelial dysfunction and wants to explore whether Vyznova (neltependocel) therapy in Japan is a realistic option, you can start with a simple, no-obligation inquiry.
We understand how hard it is to find clear, trustworthy information about a therapy this new, and how isolating that uncertainty can feel. Working within Japan's ophthalmic medical infrastructure, our specialized team gives you a direct, dependable pathway to Japan's leading corneal surgeons.
Your next step is small and easy: share your baseline details through the inquiry form below. From there, we prepare together for your remote consultation with a Japanese corneal specialist. Sending recent ophthalmic data early lets the surgical team review your candidacy carefully before you commit to any travel arrangements.
About the Author
Daiki Sakai, MD, PhD
Japanese Board-certified Ophthalmologist
Founder, Ophthoagent Team
